Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical preparation for preventing and treating progressive myopia

A myopia, medical technology, applied in the medical field, can solve the problem of no non-invasive application

Inactive Publication Date: 2016-11-16
伊万·德米崔伊维奇·扎哈洛夫 +1
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In the prior art, there is no information on the use of sclera-strengthening drugs administered non-invasively, i.e., directly into the conjunctival sac of the eye (e.g., by instillation)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation for preventing and treating progressive myopia
  • Pharmaceutical preparation for preventing and treating progressive myopia
  • Pharmaceutical preparation for preventing and treating progressive myopia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0135] Example 1. In a glass flask, while stirring with a magnetic stirrer, dissolve 0.132g (9.06×10) in 10.0ml balanced brine BBS -4 mol) Sigma’s D-lysine, and then add the amine solution as a neutralizer to 0.0652g (9.06×10) dissolved in 10.0ml distilled water -4 mol) Aldrich's polyacrylic acid (molecular weight 1800) solution, and stir for 15 minutes. An additional amount of polyacrylic acid was then used to adjust the pH to 7.4.

[0136] The prepared 1.0% by weight AFG salt solution was poured into a 5 ml volume glass bottle sterilized by high temperature sterilization at 121°C (1.1 atm) for 10 minutes.

[0137] This composition is used to strengthen the sclera. For this purpose, the composition was administered daily to the conjunctival sac of the left eye of a rabbit of the "Chinchilla" breed by instillation, and the right eye served as a complete control. Treatment includes daily instillation, twice a day for a month, with 1 to 2 drops each time. During this period and wit...

example 2

[0138] Example 2. In a glass flask, with magnetic stirring, dissolve 2.13g (1.61×10) in 70.0ml distilled water -2 mol) Sigma's L-ornithine, and then use 1.03g (0.537×10) dissolved in 26.0ml of distilled water - 2 mol) Citric acid neutralizes the dissolved amine. Then use an additional amount of sebacic acid to adjust the pH to 7.4. Via Millipore with 0.22 micron pores The prepared 3.3 wt% AFG salt solution was aseptically filtered through a membrane (PVDF), and filled into a 5 ml volume glass bottle aseptically.

[0139] As described in Example 1, the composition was used to strengthen the sclera by instillation.

example 3

[0140] Example 3. In a glass flask, when using a magnetic stirrer to stir, dissolve 0.803g (0.554×10) in 80.0ml distilled water -2 mol) Sigma’s spermidine, and then use 1.195g (1.66×10) dissolved in 18.0ml of distilled water -2 mol) Aldrich's polyacrylic acid (molecular weight 1800) neutralizes the dissolved amine. An additional amount of polyacrylic acid was then used to adjust the pH to 7.4. The prepared 2.0% by weight AFG salt solution was aseptically filtered through a Millipore membrane with 0.22 micron pores, and poured into a 5 ml volume glass bottle.

[0141] As described in Example 1, the composition was used to strengthen the sclera by instillation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to medicine, and more particularly to opthalmology, and is intended for strengthening the sclera for the purposes of preventing and treating progressive myopia. The invention is directed toward strengthening the sclera in the case of progressive myopia, reducing the time taken to strengthen the sclera, and preventing damaging, toxic and inflammatory effects on the eyeball and surrounding tissues of the eye socket during the treatment of progressive myopia. These aims are achieved through the creation and use of a pharmaceutical preparation in the form of an instillable aqueous solution or an eye gel or a medicated eye film containing an effective amount of an amine with functional groups in the form of a salt or a part of a transition metal complex compound or a combination thereof.

Description

Technical field [0001] The present invention relates to medicine, especially ophthalmology, and aims to strengthen the sclera in the case of progressive myopia. Background technique [0002] Progressive myopia is one of the most pressing problems in modern ophthalmology. Although some progress has been made in its prevention and treatment, the disease often leads to irreversible changes in the fundus of the eye and leads to a significant decrease in vision at a young working age, which causes significant restrictions on professional work and even physical disabilities (see Libman ES, Ryazanov DP, Kaleyeva EV "Disability as a result of visualimpairment in Russia". The fifth Russian national ophthalmology forum (V Russian nationalophthalmology forum). Science-practice conference foreign participants Collection of scientific works of the scientific-practical conference with participants from abroad. Moscow, 2012, 2, 797-798-[1]). [0003] In this regard, the development of new and e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/13A61K9/08A61P27/10A61K33/24
CPCA61K31/13A61K31/28A61K33/24A61K9/0048A61K9/06A61K9/08A61K9/7007A61K38/05A61K38/06A61K31/132A61K31/198A61K31/4415A61K38/02A61P27/10A61K2300/00A61K2121/00
Inventor 伊万·德米崔伊维奇·扎哈洛夫艾利克斯安德·罗伯特维奇·科瑞歌德思科
Owner 伊万·德米崔伊维奇·扎哈洛夫